Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens

被引:286
作者
Robbe, D
Alonso, G
Duchamp, F
Bockaert, J
Manzoni, OJ
机构
[1] CNRS, Unite Propre Rech 9023, F-34094 Montpellier 05, France
[2] CNRS, Unite Mixte Rech 5101, F-34094 Montpellier, France
关键词
nucleus accumbens; cannabinoid; glutamate; CB1; receptors; presynaptic inhibition; K+ channels; mice;
D O I
10.1523/JNEUROSCI.21-01-00109.2001
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Despite the role of excitatory transmission to the nucleus accumbens (NAc) in the actions of most drugs of abuse, the presence and functions of cannabinoid receptors (CB1) on the glutamatergic cortical afferents to the NAc have never been explored. Here, immunohistochemistry has been used to show the localization of CB1 receptors on axonal terminals making contacts with the NAc GABAergic neurons. Electrophysiological techniques in the NAc slice preparation revealed that cannabimimetics [WIN 55,212,2 (WIN-2) and CP55940] strongly inhibit stimulus-evoked glutamate-mediated transmission. The inhibitory actions of WIN-2 were dose-dependent (EC50 of 293 +/- 13 nM) and reversed by the selective CB1 antagonist SR 141716A. In agreement with a presynaptic localization of CB1 receptors, WIN-2 increased paired-pulse facilitation, decreased miniature EPSC (mEPSC) frequency, and had no effect on the mEPSCs amplitude. Perfusion with the adenylate cyclase activator forskolin enhanced glutamatergic transmission but did not alter presynaptic CB1 actions, suggesting that cannabinoids inhibit glutamate release independently from the cAMP-PKA cascade. CB1 did not reduce evoked transmitter release by inhibiting presynaptic voltage-dependent Ca2+ currents through N-, L-, or P/Q-type Ca2+ channels, because CB1 inhibition persisted in the presence of omega -Conotoxin-GVIA, nimodipine, or omega -Agatoxin-IVA. The K+ channel blockers 4-aminopyridine (100 muM) and BaCl2 (300 muM) each reduced by 40-50% the inhibitory actions of WIN-2, and their effects were additive. These data suggest that CB1 receptors are located on the cortical afferents to the nucleus and can reduce glutamate synaptic transmission within the NAc by modulating K+ channels activity.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 57 条
  • [1] Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons
    Auclair, N
    Otani, S
    Soubrie, P
    Crepel, F
    [J]. JOURNAL OF NEUROPHYSIOLOGY, 2000, 83 (06) : 3287 - 3293
  • [2] ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASES BY STIMULATION OF THE CENTRAL CANNABINOID RECEPTOR CB1
    BOUABOULA, M
    POINOTCHAZEL, C
    BOURRIE, B
    CANAT, X
    CALANDRA, B
    RINALDICARMONA, M
    LEFUR, G
    CASELLAS, P
    [J]. BIOCHEMICAL JOURNAL, 1995, 312 : 637 - 641
  • [3] CANNABINOID RECEPTOR AGONISTS INHIBIT CA CURRENT IN NG108-15 NEUROBLASTOMA-CELLS VIA A PERTUSSIS TOXIN-SENSITIVE MECHANISM
    CAULFIELD, MP
    BROWN, DA
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1992, 106 (02) : 231 - 232
  • [4] Occlusion of the presynaptic action of cannabinoids in rat substantia nigra pars reticulata by cadmium
    Chan, PKY
    Yung, WH
    [J]. NEUROSCIENCE LETTERS, 1998, 249 (01) : 57 - 60
  • [5] Molecular diversity of K+ channels
    Coetzee, WA
    Amarillo, Y
    Chiu, J
    Chow, A
    Lau, D
    McCormack, T
    Moreno, H
    Nadal, MS
    Ozaita, A
    Pountney, D
    Saganich, M
    Vega-Saenz de Miera, E
    Rudy, B
    [J]. MOLECULAR AND FUNCTIONAL DIVERSITY OF ION CHANNELS AND RECEPTORS, 1999, 868 : 233 - 285
  • [6] COLMERS WF, 1988, J NEUROSCI, V8, P3827
  • [7] Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction
    Cornish, JL
    Kalivas, PW
    [J]. JOURNAL OF NEUROSCIENCE, 2000, 20 (15) : art. no. - RC89
  • [8] Evidence that cannabinoid-induced inhibition of electrically evoked contractions of the myenteric plexus -: longitudinal muscle preparation of guinea-pig small intestine can be modulated by Ca2+ and cAMP
    Coutts, AA
    Pertwee, RG
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1998, 76 (03) : 340 - 346
  • [9] DEADWYLER SA, 1995, J PHARMACOL EXP THER, V273, P734
  • [10] Dittman JS, 1996, J NEUROSCI, V16, P1623